biostudies-literatureWidjaja AOSjöbergstiftelsenNilsson-Ehle EndowmentsKungliga vetenskaps och vitterhets-samhälletSwedish state under the agreement between the Swedish government and the county councils, the ALF-agreementStiftelsen Assar Gabrielssons FondGunvor and Ivan Svensson foundationSweden innovation agencyCancera foundationLions Cancerfond västCancerfonden2043-2050https://www.ebi.ac.uk/biostudies/studies/S-EPMC12922644biostudies-literatureUnknown158(8)High-grade serous ovarian carcinoma (HGSC) is the most lethal form of ovarian carcinoma, often diagnosed at advanced stages due to non-specific symptoms and the lack of reliable screening methods. This proof-of-concept study aimed to develop a robust TP53 mutation panel for detecting HGSC through targeted DNA sequencing in both liquid and solid biopsies. We constructed a custom TP53 gene panel and utilized a PCR-based unique molecular identifier approach for next-generation sequencing to analyze 94 samples from 11 patients diagnosed with HGSC, including primary tumor, plasma, ascites, ovarian cyst fluid, vaginal, endocervical and endometrial samples. Detected TP53 mutations were analyzed, categorized, and their frequencies calculated. Pathogenic TP53 mutations were identified in all patienInternational journal of cancerDetecting TP53 mutations in paired liquid and tissue biopsies from patients with high-grade serous ovarian carcinoma.PMC1292264496506521‐1848FB23‐1182021‐01145FB23-11896555222‐2080FB22‐79FB22‐67FB23‐6622-2080FB23-66FB22-6721-18482021-01145FB22-792020-0414Lindberg JHGyllensten UUlfenborg BLycke MWidjaja AOSantamaria MLCarlsson TSundfeldt KStahlberg ALinder AMicallef POsterlund TfalseDetecting TP53 mutations in paired liquid and tissue biopsies from patients with high-grade serous ovarian carcinoma.High-grade serous ovarian carcinoma (HGSC) is the most lethal form of ovarian carcinoma, often diagnosed at advanced stages due to non-specific symptoms and the lack of reliable screening methods. This proof-of-concept study aimed to develop a robust TP53 mutation panel for detecting HGSC through targeted DNA sequencing in both liquid and solid biopsies. We constructed a custom TP53 gene panel and utilized a PCR-based unique molecular identifier approach for next-generation sequencing to analyze 94 samples from 11 patients diagnosed with HGSC, including primary tumor, plasma, ascites, ovarian cyst fluid, vaginal, endocervical and endometrial samples. Detected TP53 mutations were analyzed, categorized, and their frequencies calculated. Pathogenic TP53 mutations were identified in all patien2026-01-01T00:00:00Z2026 Apr2026-07-09T11:39:42.022Z2026-07-09T10:54:15.722ZS-EPMC129226444136327410.1002/ijc.70277